Researchers have found a protein that, when inhibited in mice with cancer, increased the response to immunotherapy.
List view / Grid view
Head and Neck cancer
Inhibiting the KDM4A enzyme slowed the growth of head and neck cancer in mouse models, also demonstrating promise to aid immunotherapy.
A new study has revealed a range of genomic, proteomic and transcriptomic data about head and neck cancers, presenting possible treatment strategies.
A new cancer-killing virus called CF33 has shown success in pre-clinical trials, helping the immune system to eradicate tumours.
Researchers reveal a combination of PD1 immunotherapy and BMI1 protein inhibition eliminated cancer stem cells and prevented cancer recurrence in a mouse model.
Researchers reveal drugs inhibiting Neuropilin-1 (NRP1), a protein expressed on T cells, could improve the efficacy of immunotherapies.
Researchers reveal protospacer adjacent motif mutations (PAM sites) on the NRF2 gene of cancers could be used to guide CRISPR gene editing.
Researchers have found that there is less calmodulin binding to ion channels in the T cells from cancer patients, presenting a new immunotherapeutic target.
Drug Target Review spoke with CUE Biopharma’s President and CSO to find out how and why they created the ImmunoSTAT platform and the ways it may benefit drug design in the future.
Research demonstrated a complex of palladium and thiosemicarbazone is a more selective and powerful chemotherapeutic than the current standard of care cisplatin.
A study has shown that the SVC112 molecule can prevent cancer stem cells from producing more tumour cells in cell lines and mice, with no impact on healthy cells.
A collaborative team of researchers in the US have uncovered characteristics of tumour cells that are linked to cancer metastasis.
A research project, based out of the University of Liverpool, which will bring together a multidisciplinary team of cancer surgeons, medical oncologists and scientists in Liverpool, has been given the go ahead thanks to £200,000 worth of grant funding.